



Atty. Docket No.: PG3416US2

***In the Claims:***

A complete listing of claims 1-36 with status identifier follows.

**Claim 1 (Currently Amended): A compound of the formula:****B7**

and salts or solvates thereof.

**Claim 2 (Original): A pharmaceutical formulation, comprising: the compound of claim 1 or a pharmaceutically acceptable salt or solvate thereof together with one or more pharmaceutically acceptable carriers, diluents, or excipients.****Claim 3 (Currently Amended): A method of treating a susceptible cancer in a human or animal subject mammal, comprising administering to said subject an effective amount of a compound as claimed in claim 1, wherein said cancer is breast cancer, gastric cancer or head and neck cancer.****B**

Atty. Docket No.: PG3416US2

Claim 4 (Currently Amended): A method as claimed in claim 3, wherein the susceptible cancer is a susceptible breast cancer.

Claims 5-6 (Cancelled)

<sup>5</sup>  
Claim 7 (Currently Amended): A method as claimed in claim 3, wherein the susceptible cancer is a susceptible stomach gastric cancer.

Claim 8 (Cancelled)


Claim 9 (Currently Amended): A method as claimed in claim 3, wherein the susceptible cancer is a susceptible head and neck cancer.

*B1*  
Claim 10 (Currently Amended): ~~A method as claimed in claim 3, wherein the susceptible cancer is a susceptible cancer characterized by expression or over-expression of EGFR.~~


Claim 11 (Currently Amended): ~~A method as claimed in claim 3, wherein the susceptible cancer is a susceptible cancer characterized by expression or over-expression of erbB-2.~~

Claim 12 (Currently Amended): ~~A method as claimed in claim 3, wherein the susceptible cancer is a susceptible cancer characterized by expression or over-expression of EGFR and erbB-2.~~

Claim 13 (Currently Amended): A compound of the formula:



Atty. Docket No.: PG3416US2



and salts or solvates thereof.

8  
Claim 14 (Previously Presented): A pharmaceutical formulation, comprising: the compound of claim 13 or a pharmaceutically acceptable salt or solvate thereof together with one or more pharmaceutically acceptable carriers, diluents, or excipients.

9  
B1  
Claim 15 (Currently Amended): A method of treating a susceptible cancer in a human or animal subject mammal, comprising administering to said subject an effective amount of a compound as claimed in claim 13, wherein said cancer is breast cancer, gastric cancer or head and neck cancer.

10.  
Claim 16 (Currently Amended): A method as claimed in claim 15, wherein the susceptible cancer is a-susceptible breast cancer.

Claims 17-18 (Cancelled)

11.  
Claim 19 (Currently Amended): A method as claimed in claim 15, wherein the susceptible cancer is a-susceptible stomach gastric cancer.

Claim 20 (Cancelled)

12.  
Claim 21 (Currently Amended): A method as claimed in claim 15, wherein the susceptible cancer is a-susceptible head and neck cancer.

13

Atty. Docket No.: PG3416US2

~~Claim 22 (Currently Amended): A method as claimed in claim 1615, wherein the susceptible cancer is a susceptible cancer characterized by expression or over-expression of EGFR.~~



~~Claim 23 (Currently Amended): A method as claimed in claim 1615, wherein the susceptible cancer is a susceptible cancer characterized by expression or over-expression of erbB-2.~~

~~Claim 24 (Currently Amended): A method as claimed in claim 1615, wherein the susceptible cancer is a susceptible cancer characterized by expression or over-expression of EGFR and erbB-2.~~

*B1*

*13*

~~Claim 25 (Currently Amended): A compound of the formula:~~



and salts or solvates thereof.

*14*

~~Claim 26 (Previously Presented): A pharmaceutical formulation, comprising: the compound of claim 25 or a pharmaceutically acceptable salt or solvate thereof together with one or more pharmaceutically acceptable carriers, diluents, or excipients.~~

*B*

Atty. Docket No.: PG3416US2

15

Claim 27 (Currently Amended): A method of treating a susceptible cancer in a human or animal subject mammal, comprising administering to said subject an effective amount of a compound as claimed in claim 25, wherein said cancer is breast cancer, gastric cancer or head and neck cancer.

16

Claim 28 (Currently Amended): A method as claimed in claim 27, wherein the susceptible cancer is a-susceptible breast cancer.

15

Claims 29-30 (Cancelled)

17

Claim 31 (Currently Amended): A method as claimed in claim 27, wherein the susceptible cancer is a-susceptible stomach gastric cancer.

B1

Claim 32 (Cancelled)

18

Claim 33 (Currently Amended): A method as claimed in claim 27, wherein the susceptible cancer is a-susceptible head and neck cancer.

15

Claim 34 (Currently Amended): A method as claimed in claim 27, wherein the susceptible cancer is a-susceptible cancer characterized by expression or over-expression of EGFR.

C

Claim 35 (Currently Amended): A method as claimed in claim 27, wherein the susceptible cancer is a-susceptible cancer characterized by expression or over-expression of erbB-2.

Claim 36 (Currently Amended): A method as claimed in claim 27, wherein the susceptible cancer is a-susceptible cancer characterized by expression or over-expression of EGFR and erbB-2.

B